21 February 2024 in Nature
Interleukin-10 (IL-10) is a key anti-inflammatory cytokine that can limit immune cell activation and cytokine production in innate immune cell types1. Loss of IL-10 signalling results in life-threatening inflammatory bowel disease in humans and mice—however, the exact mechanism by which IL-10 signalling subdues inflammation remains unclear2–5. Here we find that increased saturated very long chain (VLC) ceramides are critical for the heightened inflammatory gene expression that is a hallmark of IL-10 deficiency. Accordingly, genetic deletion of ceramide synthase 2 (encoded by Cers2), the enzyme responsible for VLC ceramide production, limited the exacerbated inflammatory gene expression programme associated with IL-10 deficiency both in vitro and in vivo. The accumulation of saturated VLC ceramides was regulated by a decrease in metabolic flux through the de novo mono-unsaturated fatty acid synthesis pathway. Restoring mono-unsaturated fatty acid availability to cells deficient in IL-10 signalling limited saturated VLC ceramide production and the associated inflammation. Mechanistically, we find that persistent inflammation mediated by VLC ceramides is largely dependent on sustained activity of REL, an immuno-modulatory transcription factor. Together, these data indicate that an IL-10-driven fatty acid desaturation programme rewires VLC ceramide accumulation and aberrant activation of REL. These studies support the idea that fatty acid homeostasis in innate immune cells serves as a key regulatory node to control pathologic inflammation and suggests that ‘metabolic correction’ of VLC homeostasis could be an important strategy to normalize dysregulated inflammation caused by the absence of IL-10.
1 January 2025 in Immune Network
Mattingly JR, et al. Immune Netw. 2025 Feb;25(1):e11. https://doi.org/10.4110/in.2025.25.e11
25 October 2025 in bioRxiv
Summary: Atopic dermatitis is an allergic skin disease associated with a profound reorganization of the epidermal lipidome. The effect of the altered lipidome on the skin-resident immune cells that drive disease is unclear. Previous reports identified Fatty acid binding protein 5 (FABP5) as a biomarker for atopic dermatitis, yet how FABP5 might contribute to disease pathogenesis is unknown. Here, we use a murine model of atopic dermatitis, to demonstrate that FABP5 is highly expressed in immune and epithelial cell lineages and that FABP5 protects against skin inflammation. Lipidomic analysis revealed that FABP5 deficiency broadly disrupts the systemic abundance of ether-linked lipids, a minor but important subset of glycerophospholipids. We show that these changes in ether lipid abundance are crucial for the proper regulation of platelet activating factor (PAF), a potent inflammatory ether lipid derivative. Concordantly, we observe elevated PAF in FABP5-deficient mice with dermatitis and that depletion of basophils, a major source of PAF, is sufficient to ameliorate disease in these animals. Altogether, our findings reveal a novel role for FABP5 in the control of allergic inflammation through the modulation of ether lipid and PAF metabolism.
24 September 2026 in Science
Mechanisms by which primary tumor cells acquire metastatic capability through metabolic and signaling adaptations are currently poorly understood. We demonstrate that tumor-intrinsic ceramide metabolism, amplified by dietary fat, initiates colorectal cancer metastasis. We observed that dietary fat exposure triggers a sustained increase in de novo ceramide biosynthesis, mediated by the dihydroceramide desaturase Degs1 . Ceramide accumulation activates yes-associated protein (YAP) through protein phosphatase 2A (PP2A)–mediated dephosphorylation, promoting a durable shift toward a distinct YAP-driven regenerative (YAP-DR) program, marked by Basp1 , that promotes metastasis. Selective elimination of
Basp1
high
cancer cells prevented metastatic seeding. Degs1 loss reduced ceramide levels, YAP activity, YAP-DR signatures, and metastasis without affecting primary tumor growth, whereas blocking ceramide degradation enhanced YAP activity and metastasis. These findings identify ceramide-induced YAP signaling as a key mediator of metastatic initiation, operating independently of primary tumor expansion.
5 November 2026 in Research Square
IL-4 is a pleiotropic cytokine that was first identified as a B cell co-mitogen over 30 years ago1. However, how IL-4 signaling mechanistically supports B cell proliferation is incompletely understood. Here, we find that the cholesterol biosynthetic program is transcriptionally upregulated by IL-4 signaling during the early B cell response to influenza virus infection and is required for B cell activation in vivo. Induction of lipid synthesis genes required both STAT6 and SREBP2 transcription factors, allowing IL-4 activated B cells to enter the cell cycle and proliferate in the absence of lipids. Genetic inhibition of de novo cholesterol synthesis via SREBP2 deletion reduced plasmablasts and subsequent germinal center B cell formation at steady state and following influenza infection. SREBP2-deficency blocked IL-4 mediated cell cycle entry, ER expansion, and subsequent proliferation in a cholesterol dependent manner. Further mechanistic studies revealed that ER cholesterol content promoted sustained STAT6 signaling associated with ER expansion and B cell survival. In sum, we demonstrate that the well-known ability of IL-4 to act as a B cell growth factor is through a previously unknown rewiring of specific lipid anabolic programs, relieving sensitivity of cells of environmental nutrient availability.